PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Recruiting

Conditions: Migraine

Interventions: Other: Rimegepant
Other: Not taking Rimegepant

First Posted Date: 2021-09-16

Last Posted Date: 2024-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 780

Registration Number: NCT05046613

Locations: 🇺🇸
PPD, Morrisville, North Carolina, United States

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + aromatase inhibitor
Drug: Aromatase inhibitor

First Posted Date: 2021-09-14

Last Posted Date: 2024-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 1939

Registration Number: NCT05043506

Locations: 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇩🇪
Medizinische Studiengesellschaft NORD-WEST GmbH, Westerstede, Germany
🇩🇪
Ruppiner Kliniken GmbH, Neuruppin, Ostprignitz-ruppin, Germany

and more 61 locations

A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: ritlecitinib

First Posted Date: 2021-09-10

Last Posted Date: 2023-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05040295

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Active, not recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Apixaban
Drug: Rivaroxaban
Drug: Dabigatran
Drug: Vitamin K antagonist (VKA)

First Posted Date: 2021-09-09

Last Posted Date: 2024-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05038228

Locations: 🇬🇧
Pfizer Investigator, London, United Kingdom

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06823859
Drug: Placebo

First Posted Date: 2021-09-08

Last Posted Date: 2023-12-15

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT05037409

Locations: 🇯🇵
Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: GBT021601

First Posted Date: 2021-09-05

Last Posted Date: 2023-07-25

Lead Sponsor: Pfizer

Target Recruit Count: 129

Registration Number: NCT05036512

Locations: 🇦🇺
Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

and more 1 locations

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

Phase 3

Recruiting

Conditions: Lower Respiratory Tract Illness

Interventions: Biological: Placebo
Biological: RSVpreF

First Posted Date: 2021-09-05

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 38567

Registration Number: NCT05035212

Locations: 🇺🇸
St. Vincent's Birmingham (Pharmacy), Birmingham, Alabama, United States
🇺🇸
St. Vincent's Birmingham, Birmingham, Alabama, United States
🇺🇸
Medical Affiliated Research Center, Huntsville, Alabama, United States

and more 272 locations

Korea Comirnaty Post-marketing Surveillance

Active, not recruiting

Conditions: COVID-19
Vaccines
SARS-CoV-2
Safety
Adverse Effects

Interventions: Biological: Riltozinameran 12 Years of age and older
Biological: Famtozinameran 12 Years of age and older
Biological: Raxtozinameran 12 years of age and older
Biological: Tozinameran 12 Years of age and older
Biological: Raxtozinameran 6 months to 4 years of age
Biological: Tozinameran 5 to 11 Years of age
Biological: Famtozinameran 5 to 11 Years of age
Biological: Tozinameran 6 months to 4 years of age

First Posted Date: 2021-09-02

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 18000

Registration Number: NCT05032976

Locations: 🇰🇷
Pfizer Inc, Seoul, Korea, Republic of

Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Bosutinib capsule
Drug: Bosutinib

First Posted Date: 2021-09-02

Last Posted Date: 2022-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT05032690

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Ritonavir + Midazolam
Drug: PF-07321332/ritonavir + Midazolam
Drug: Midazolam

First Posted Date: 2021-09-02

Last Posted Date: 2023-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05032950

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy